All In Biotech

Drug Trial Radar · NCT06456463

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Actual

Start

Jan 14, 2025

Primary completion

Feb 9, 2028

Study completion Feb 11, 2030

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • TagraxofuspDrug

    Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.

  • VenetoclaxDrug

    Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.

  • AzacitidineDrug

    Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Determination of Part 2 Selected Dose of Tagraxofusp When Administered in Combination with Venetoclax and AzacitidineTime frame: Cycles 1-4 (up to 112 days; 28 days/cycle)
  2. Part 2: Number of Participants Achieving a Best Overall Response (BOR) of Complete Remission (CR)Time frame: Cycles 1-4 (up to 112 days; 28 days/cycle)

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford Health Care

    Stanford, California

  • University of Miami

    Miami, Florida

  • AdventHealth Cancer Institute

    Orlando, Florida

  • University of Chicago

    Chicago, Illinois

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Henry Ford Health System Brigitte Harris Cancer Pavillion

    Detroit, Michigan

  • Washington University - Siteman Cancer Center

    St Louis, Missouri

  • John Theurer Cancer Center - Hackensack Meridian Health

    Hackensack, New Jersey

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • North Shore University Hospital

    Manhasset, New York

  • NYU Langone Health

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina

  • Novant Health Derrick L Davis Cancer Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Sydney Kimmel (Thomas Jefferson University)

    Philadelphia, Pennsylvania

  • Sarah Cannon, the Cancer Institute of HCA Healthcare

    Nashville, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Baylor Scott & White Health

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Townsville Hospital

    Douglas, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • St. Vincents Hospital

    Fitzroy, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.